Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences
05. August 2020 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Announces Changes to Board of Directors
02. Juli 2020 07:30 ET
|
Harpoon Therapeutics
Joanne Viney, Ph.D., brings expertise as an immunologist and veteran biotech executive to the board Drs. Luke Evnin and Patrick Baeuerle step down from the Harpoon board Dr. Baeuerle remains as...
Harpoon Therapeutics Updates Information for its Participation in Two Upcoming Virtual Conferences
17. Juni 2020 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences
11. Juni 2020 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., June 11, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Presents Interim Phase 1 Data from an Ongoing Dose Escalation Trial for the PSMA-targeting TriTAC® HPN424 at the ASCO20 Virtual Scientific Program
29. Mai 2020 08:00 ET
|
Harpoon Therapeutics
The on-going dose escalation Phase 1 study has enrolled 44 patients with progressive, metastatic castration-resistant prostate cancer in 11 cohorts. Initial safety data showed that HPN424 is generally...
Harpoon Therapeutics to Present Interim Clinical Data for TriTAC® HPN424 at the ASCO20 Virtual Scientific Program
22. Mai 2020 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 22, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced...
Harpoon Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
06. Mai 2020 16:05 ET
|
Harpoon Therapeutics
Dosed first patient with HPN217 for the treatment of multiple myeloma, triggering a $50 million milestone payment from AbbVieAbstract for HPN424 interim Phase 1 data accepted for presentation at...
Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple Myeloma
27. April 2020 06:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Appoints Two New Members to Its Board of Directors
01. April 2020 07:30 ET
|
Harpoon Therapeutics
Andrew R. Robbins, former Chief Operating Officer, Array BiopharmaDr. Joseph S. Bailes, former President of American Society of Clinical Oncology (ASCO) SOUTH SAN FRANCISCO, Calif., April 01, 2020 ...
Harpoon Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Corporate Update
12. März 2020 16:05 ET
|
Harpoon Therapeutics
Exclusive worldwide option and license transaction for HPN217 with AbbVie and expansion of existing discovery collaboration in November 2019 could provide up to $100 million in upfront/near-term...